The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing of New Ordinary Shares

22 Mar 2011 07:00

RNS Number : 3574D
PuriCore Plc
22 March 2011
 



PuriCore plc

(the "Company")

Placing of New Ordinary Shares

 

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 22 March 2011 - PuriCore (LSE: PURI), the water-based clean technology company, is pleased to announce that it has raised £1.2 million by way of a Placing (the "Placing") of 2,272,727 new ordinary shares of 10 pence each ("Ordinary Shares") in the Company (the "Placing Shares").

 

The Placing has been completed at a price of 52.8 pence per Placing Share representing a premium of approximately 5.6% per cent. to the closing mid-market price per Ordinary Share on 21 March 2011.

 

The net proceeds of the Placing will be used to provide working capital to the Company, giving it additional financial flexibility and to facilitate growth.

 

Application has been made for the Placing Shares to be admitted to the Official List of the UK Listing Authority and to trading on the main market for listed securities of the London Stock Exchange Plc, respectively. Dealings in the Placing Shares are expected to commence at 8:00a.m. on 23 March 2011 ("Admission").

 

Commenting on the Placing, Chris Wightman, Executive Chairman, said:

 

"Today's placing provides PuriCore with additional working capital at a time of global uncertainty. It will enable us to continue to build sales and market share in our US food business where the advantages of our unique chemistry have been validated by many of the largest food retailers in the US and where we are now expanding into the floral industry. We believe that, with the new formulations now available to us, we have the potential to expand our technology quickly into new markets, including wound management and agriculture, and look forward to reporting progress when we deliver our final results."

 

 

Enquiries:

Financial Dynamics

Susan Quigley

Ben Brewerton

+44 (0) 20 7831 3113

PuriCore

Chris Wightman

Executive Chairman

+44 (0) 20 7290 3440

 

 

About PuriCore

PuriCore plc is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

 

Details of the Placing

The Company has raised £1.2 million (before expenses) by the issue of 2,272,727 Placing Shares. The Placing Shares represent approximately 9.09 per cent. of the enlarged share capital of the Company.

 

The Company has conditionally placed the Placing Shares with institutional and private investors at a price of 52.8 pence per share.

 

The Placing Price represents a premium of approximately 5.6 per cent. to the closing mid-market price of 50.0 pence per Ordinary Share on 21 March 2011, being the last dealing day prior to the release of this announcement. The Placing Shares will represent an increase of approximately 9.998 per cent. in the current issued share capital of the Company. Following Admission of the Placing Shares, the Company will have a total of 25,003,770 Ordinary Shares in issue.

 

It is anticipated that dealings in the Placing Shares will commence at 8:00 a.m. on 23 March 2011. The Placing is conditional, inter alia, upon Admission becoming effective no later than 8:00 a.m. on 23 March 2011 or such later date (being not later than 8.00 a.m. on 22 April 2011) as the Company shall determine.

 

The Placing Shares will be issued credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared or paid thereon following Admission.

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEDKDDQNBKBANB
Date   Source Headline
18th Aug 20167:00 amRNSBlock listing Interim Review
17th Aug 20167:00 amRNSPuriCore Receives Two U.S. Patents
16th Jun 201611:39 amRNSResult of AGM
9th Jun 20167:00 amRNSCompletion of Pre-IND Meeting with FDA on PR022
27th May 20167:00 amRNSResolution reached with EPA
14th Apr 20167:00 amRNSAppointment of Dr. Christian Peters as CMO
31st Mar 20167:00 amRNSNotice of AGM
29th Mar 20163:11 pmRNSDirector Dealing
29th Mar 20167:00 amRNSGrant of Options
24th Mar 20163:22 pmRNSAnnual Financial Report
24th Mar 20167:00 amRNSFinal Results
1st Mar 20167:00 amRNSAppointment of Dr Simba Gill to the Board
19th Feb 20169:30 amRNSBlocklisting Interim Review
8th Feb 20167:00 amRNSStrategic Review and Trading Update
4th Jan 201610:21 amRNSHolding(s) in Company
21st Dec 20158:55 amRNSHolding(s) in Company
14th Oct 20155:13 pmRNSDirector Dealing
30th Sep 20156:08 pmRNSHolding(s) in Company
28th Sep 20157:00 amRNSDirector Dealings
23rd Sep 20157:00 amRNSHalf Yearly Report
19th Aug 20158:33 amRNSBlocklisting Interim Review
1st Jul 20157:00 amRNSChange of Registered Office
19th Jun 20157:00 amRNSBoard Changes
18th Jun 201511:00 amRNSResult of AGM
9th Jun 20155:02 pmRNSGrant of Options
19th May 20157:00 amRNSAppointment of Alex Martin as CEO
2nd Apr 20157:00 amRNSDirector Dealing
31st Mar 20157:00 amRNSFinal Results
30th Mar 201512:22 pmRNSHolding(s) in Company
19th Mar 20157:00 amRNSSigns Major Supermarket Deal
24th Feb 20157:00 amRNSTrading Update
17th Feb 20158:24 amRNSBlocklisting Interim Review
9th Jan 20157:00 amRNSHolding(s) in Company
23rd Dec 20148:00 amRNSCancellation - PuriCore Plc
23rd Dec 20147:00 amRNSPuricore commences trading on AIM
25th Nov 20147:00 amRNSStrategic and Operational Review Update
24th Nov 20142:03 pmRNSResult of General Meeting
7th Nov 20147:00 amRNSProposed listing changes and notice of GM
5th Nov 20147:00 amRNSPuriCore granted two U.S. patents
31st Oct 20147:00 amRNSInterim Management Statement
14th Oct 20147:00 amRNSPlanned Directorate Changes
12th Aug 201411:49 amRNSDirector Dealing
11th Aug 20147:00 amRNSBlocklisting Interim Review
8th Aug 20147:00 amRNSHalf Yearly Report
31st Jul 20141:51 pmRNSNotice of Results
11th Jul 20147:00 amRNSTrading Update and Strategic Review
1st Jul 20147:00 amRNSCompletes Sale of UK Endoscopy Business
23rd Jun 20147:00 amRNSBoard Changes
20th Jun 201410:59 amRNSResult of General Meeting
19th Jun 201411:49 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.